The PROSPECT Study

The Prospect Study

Who Can Participate in the PROSPECT Study?

Adults at least 18 years of age who have been diagnosed with Relapsed or Refractory PCNSL (PCNSL that did not improve or only temporarily improved from previous treatment with high-dose methotrexate) may be eligible to participate.

These are not the only eligibility criteria for this research study. A clinical research team member will help determine if this study is right for you based on all eligibility criteria.

If you are interested in participating, please complete the Pre-Screener with your information to learn more.

About the PROSPECT Study

Relapsed or refractory primary central nervous system lymphoma (R/R PCNSL) is a type of cancer that either does not improve from treatment (refractory) or improves only for a limited time (relapsed). Current treatment options for R/R PCNSL are limited, and there are no medications approved specifically for the treatment of PCNSL in the United States. New treatment options are needed to improve the prognosis for those with R/R PCNSL.

Before a new medicine can become available to the public, it must first be tested in a series of clinical trials. The PROSPECT study is evaluating the safety and effectiveness of an investigational oral medicine called Tirabrutinib for potential treatment of R/R PCNSL patients who have had at least 1 prior methotrexate contained regimen. About 45 participants will be enrolled in the the PROSPECT study in the United States.

By choosing to volunteer, you can help make a difference for thousands of others diagnosed with PCNSL.

Tirabrutinib has been approved and is currently marketed in Japan for R/R PCNSL patients.

What to Expect

If you choose to participate, the study team will complete a thorough screening to ensure you meet the requirements for this study. Screening will include a physical exam, blood and urine samples, echocardiogram, ECG, eye exam, chest X-ray, CT, MRI and/or PET scans, lumbar puncture, and possible biopsy.

All participants will receive Tirabrutinib that will be taken orally once a day in multiple 28-day cycles. Tirabrutinib should be taken on an empty stomach at approximately the same time every day. Participants may not receive other cancer treatments or therapies during their time in the study.

The number of study treatment cycles completed will vary. You may continue taking Tirabrutinib for as long as you and your doctor believe it is of benefit to you. You may choose to leave the study at any time, for any reason. Choosing to not participate will not impact your future medical care in any way.

You will need to attend regular appointments so the study team can monitor how you are responding to the study medicine. You will have an additional follow-up visit about 1 month after completing your final treatment cycle, and the study team will call you to check in about every 6 months thereafter.

So far – So good!

You appear to meet the basic requirements for the PROSPECT Study! However, only the research study staff can fully determine if you qualify to enroll. Please enter your contact information and select "Find a Site" to see if there is a study site enrolling in your area.

Sorry, you are not eligible at this time.

Thank you for your interest in the PROSPECT Study. Please contact your healthcare provider if you have any medical questions. Also, please consider entering your information below to be contacted about future clinical research opportunities.

Question 1 of 2

Are you at least 18 years of age?

Yes

Question 2 of 2

Have you been diagnosed with Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)?

Yes

First Name *

Last Name *

Phone Number *

E-Mail *

Address *

manual address entry

Address 1 *

Address 2

City *

State *

ZIP code

Country *

Latitude

Longditude

Please select a full valid address.

How did you hear about us?

Choose a Location

See below to select a research site near you. If you don't see a site near you, then select "The sites listed here are not convenient for me." Study locations are being added regularly. A study representative will call you if a research site becomes available in your area.

The sites listed here are not convenient for me.

Leave this field blank